

14th Annual HCP Conference

27-29 May 2026
Boulder, CO, USA



Workshop 1: From Basic Analytics to Advanced Analytical Characterization

Tackling the “Bad Actors” for a Systematic HCP Risk Control and Exploring Opportunities to Update USP

Workshop Leaders:

Kevin Van Cott, U of Nebraska-Lincoln

Fengqiang Wang, Merck & Co., Inc


Ying Zhang, Eli Lilly and Company

Lisette Coye, Coye CMC Strategies


Audience Surveys



W1.1 What best describes your experience with HCP analytics?



W1.2 What types of molecules do you primarily work with?




W1.3 If you answered "other emerging modalities" in the previous question, can you specify?



aavs glp1 peptide
bite na aav
t cell engager


W1.4 Which analytical approaches does your organization currently use for HCP monitoring?



W1.5 If you answered "other analytical methods", can you specify what kind of methods you are using?



W1.6 Which of the following best describes your current role in HCP analytics?




W1.7 If the answer is "other" to the previous question, please specify


A large, light blue watermark logo is centered on the slide. It consists of a globe with the acronym 'BEBPA' overlaid in large, semi-transparent letters. The words 'BIOPHARMACEUTICAL' and 'EMERGING' are arched above the globe, and 'BEST PRACTICES ASSOCIATION' is arched below it.

standardization
process development
business development
consultant

W1.8 Which of the following topics would you prefer to learn about or discuss during the workshop?




W1.9 Which of the following case studies are you most interested in learning more about?



W1.10 If answered "other cases" for the previous question, please specify the cases you are interested in learning about.




W1.11 Which areas in USP <1132> (Residual Host Cell Protein Measurement in Biopharmaceuticals) warrant updating?



W1.12 If answered "other areas" for the previous question, please specify the areas need update



W1.13 What HCP coverage analysis does your company/organization use?









Thank you!!